Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb 10;6(3):e1290037. doi: 10.1080/2162402X.2017.1290037

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 1. — CD16 engagement by obinutuzumab-opsonized targets enhances both CD107a mobilization and IFNγ production. PBMCs were left alone (baseline) or combined (2:1) with rituximab (Raji-RTX)-, obinutuzumab (Raji-GA101)-, wt-GA101 (Raji-wt-GA101)-opsonized or non-opsonized Raji (Raji-Ctrl) for 6 h. The percentage of IFNγ⁺ and CD107a⁺ cells among NK cells (CD3⁻CD56⁺) were analyzed by flow cytometry. (A) Plots from one representative donor are shown. (B) Data (mean ± SEM) from nine donors are shown. *p < 0.05, **p < 0.01, ***p < 0.0001. Compared to baseline or Raji-Ctrl samples, all the differences were statistically significant (p < 0.0001). (C) The median fluorescence intensity (FI) values of IFNγ NK cells from nine individuals are reported in the graph. Each line represents a single donor. **p < 0.01, ***p < 0.0001.